Physician profile
Stuart R Gordon
NPI 1992711469
$42,212.88
in general payments reported to CMS, 2019-2025
7 companies · $350 in 2025
The $350 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,060 · 2020: $4,186 · 2021: $8,009 · 2022: $425 · 2023: $22K · 2024: $3,678 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Consulting Fee: $7,500 · Travel and Lodging: $1,671 · Honoraria: $350 · Food and Beverage: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,820.00 |
| Consulting Fee | $7,500.00 |
| Travel and Lodging | $1,671.00 |
| Honoraria | $350.00 |
| Food and Beverage | $192.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $38,160.26 | 2019-2024 | Exalt Model D |
| Ipsen Biopharmaceuticals, INC | $3,320.00 | 2023 | |
| Vascular Technology, INC. | $350.00 | 2025 | |
| Lumendi LLC | $235.62 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $147.00 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.